ASCO25: PanGIA Biotech’s AI-based urine test for prostate cancer hits trial success
With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA Biotech has shared results from a study validating its artificial intelligence (AI)-based liquid biopsy in vitro diagnostic (IVD) for detecting early prostate cancer from urine samples. The post ASCO25: PanGIA Biotech’s AI-based urine test for prostate cancer hits trial success appeared first on Medical Device Network.
With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA Biotech has shared results from a study validating its artificial intelligence (AI)-based liquid biopsy in vitro diagnostic (IVD) for detecting early prostate cancer from urine samples.
The post ASCO25: PanGIA Biotech’s AI-based urine test for prostate cancer hits trial success appeared first on Medical Device Network.
